These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36541839)

  • 1. Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists.
    Pulver B; Riedel J; Schönberger T; Halter S; Lucas T; Opatz T; Grafinger KE; Scheu M; Zschiesche A; Pütz M; Pützer K; Westphal F; Auwärter V
    Drug Test Anal; 2023 Apr; 15(4):408-425. PubMed ID: 36541839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and
    Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
    ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA.
    Haschimi B; Grafinger KE; Pulver B; Psychou E; Halter S; Huppertz LM; Westphal F; Pütz M; Auwärter V
    Drug Test Anal; 2021 Aug; 13(8):1499-1515. PubMed ID: 33788409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Characterization of a Systematic Library of Alkyl and Alicyclic Synthetic Cannabinoids Related to CUMYL-PICA, CUMYL-BUTICA, CUMYL-CBMICA, and CUMYL-PINACA.
    Janssens LK; Ametovski A; Sparkes E; Boyd R; Lai F; Maloney CJ; Rhook D; Gerona RR; Connolly M; Liu H; Hibbs DE; Cairns EA; Banister SD; Stove CP
    ACS Chem Neurosci; 2023 Jan; 14(1):35-52. PubMed ID: 36530139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.
    Banister SD; Adams A; Kevin RC; Macdonald C; Glass M; Boyd R; Connor M; McGregor IS; Havel CM; Bright SJ; Vilamala MV; Lladanosa CG; Barratt MJ; Gerona RR
    Drug Test Anal; 2019 Feb; 11(2):279-291. PubMed ID: 30151911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD
    Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
    Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
    Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining Steric Requirements at CB
    Markham J; Sparkes E; Boyd R; Chen S; Manning JJ; Finlay D; Lai F; McGregor E; Maloney CJ; Gerona RR; Connor M; McGregor IS; Hibbs DE; Glass M; Kevin RC; Banister SD
    ACS Chem Neurosci; 2022 Apr; 13(8):1281-1295. PubMed ID: 35404067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human phase-I metabolism of three synthetic cannabinoids bearing a cumyl moiety and a cyclobutyl methyl or norbornyl methyl tail: Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, and Cumyl-NBMINACA.
    Giorgetti A; Brunetti P; Haschimi B; Pulver B; Pascali JP; Riedel J; Auwärter V
    Drug Test Anal; 2024 Sep; ():. PubMed ID: 39218806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA.
    Ametovski A; Macdonald C; Manning JJ; Haneef SAS; Santiago M; Martin L; Sparkes E; Reckers A; Gerona RR; Connor M; Glass M; Banister SD
    ACS Chem Neurosci; 2020 Nov; 11(21):3672-3682. PubMed ID: 33054155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?
    Ametovski A; Cairns EA; Grafinger KE; Cannaert A; Deventer MH; Chen S; Wu X; Shepperson CE; Lai F; Ellison R; Gerona R; Blakey K; Kevin R; McGregor IS; Hibbs DE; Glass M; Stove C; Auwärter V; Banister SD
    ACS Chem Neurosci; 2021 Nov; 12(21):4020-4036. PubMed ID: 34676751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).
    Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V
    Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
    Wilson CD; Hiranita T; Fantegrossi WE
    Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.